论文部分内容阅读
目的探讨罗格列酮治疗2型糖尿病的临床疗效。方法将口服磺脲类降糖药血糖控制不满意的2型糖尿病患者88例随机分为治疗组和对照组各44例,对照组在磺脲类降糖药物的基础上加服盐酸二甲双胍250mg,3次/d,治疗组加服罗格列酮4mg,1次/d,疗程均为12周,比较治疗前后两组的空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbAlc)、空腹胰岛素(FINS)、总胆固醇(Tc)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-c)、低密度脂蛋白胆固醇(LDI-c)的变化。结果两组治疗后与治疗前比较FBG、2hBG、HbA1C、FINS、Tc、TG、HDL-c、LDL-c均显著降低,差异有统计学意义(P<0.05),而治疗组与对照组比较经治疗后上述指标均明显降低,HDL-C增高,差异有统计学意义(P<0.05)。结论罗格列酮治疗2型糖尿病不但能改善胰岛素抵抗、降低血糖、改善脂质代谢紊乱,还能延缓糖尿病的发展及降低发生血管并发症的危险,从而改善患者的远期预后,且治疗后无明显不良反应,值得临床推广使用。
Objective To investigate the clinical efficacy of rosiglitazone in the treatment of type 2 diabetes mellitus. Methods Eighty-eight patients with type 2 diabetes who were not satisfied with oral administration of sulfonylurea hypoglycemic agents were randomly divided into treatment group (44 cases) and control group (44 cases). The control group received metformin hydrochloride (250 mg) 3 times / d, the treatment group plus rosiglitazone 4mg, 1 / d, treatment for 12 weeks, before and after treatment compared fasting blood glucose (FBG), 2h postprandial blood glucose (2hPG), HbAlc , Fasting insulin (FINS), total cholesterol (Tc), triglyceride (TG), high density lipoprotein cholesterol (HDL-c) and low density lipoprotein cholesterol (LDI-c) Results The FBG, 2hBG, HbA1C, FINS, Tc, TG, HDL-c and LDL-c in the two groups after treatment were significantly lower than those before treatment, with statistical significance (P <0.05) After treatment, the above indicators were significantly lower, HDL-C increased, the difference was statistically significant (P <0.05). Conclusion Rosiglitazone treatment of type 2 diabetes not only improves insulin resistance, reduces blood glucose, improves lipid metabolism disorders, but also delays the development of diabetes and reduces the risk of vascular complications, thereby improving the long-term prognosis of patients, and after treatment No significant adverse reactions, it is worth to promote clinical use.